IL Receptor

Ro26-4550 is a potent antagonist of IL-2/IL-2Rα binding, exhibiting an IC50 value of 3 μM. This compound is valuable for investigating the modulation of IL-2 signaling pathways, which play a critical role in T cell proliferation and immune response regulation. Research applications include studying autoimmune diseases, cancer immunotherapy, and potential therapeutic interventions targeting IL-2-mediated effects.

K-832 is an orally active inhibitor of IL-1β secretion, targeting the interleukin-1 pathway. This compound demonstrates significant biological activity by reducing inflammatory responses associated with autoimmune disorders. K-832 is applicable in the research of rheumatoid arthritis and other conditions linked to elevated IL-1β levels, making it a valuable tool for studying inflammation and immune response modulation.

IL-17 Modulator 9 is an orally active inhibitor targeting the IL-17 pathway. This compound significantly reduces levels of pro-inflammatory cytokines such as IL-6 and IFN-γ while also diminishing edema. It serves as a valuable tool for studying various inflammatory conditions and exploring therapeutic interventions.

Anflekitug is a CHO-expressed human antibody that specifically targets interleukin-1 beta (IL-1β). This monoclonal antibody features a huIgG1 heavy chain and a huκ light chain, exhibiting a predicted molecular weight of 145 kDa. Anflekitug is suitable for applications in inflammatory research, including studies of autoimmune diseases and cytokine signaling pathways. For isotype control experiments, human IgG1 kappa may be used as an appropriate reference.

IL-17 modulator 10 is a potent inhibitor of the IL-17 signaling pathway, demonstrating an IC50 of 0.71 μM in HTRF assays that evaluate the binding of IL-17A to IL-17RA. This compound is particularly relevant for research focused on autoimmune and inflammatory diseases, providing valuable insights into therapeutic interventions targeting IL-17-mediated pathways.

IL-17 Modulator 2 is an orally active compound that targets the IL-17 pathway. It is effective in significantly reducing levels of pro-inflammatory cytokines, including IL-6 and IFN-γ, while also decreasing edema. This reagent is suited for research applications related to arthritis and other inflammatory conditions.

E5090 is an orally active inhibitor of IL-1 generation, acting through its conversion in vivo to the active deacetylated form, DA-E5090. This compound exhibits significant anti-inflammatory properties, making it valuable for studies related to inflammation and immune response modulation. E5090 is useful in various immunology research applications, particularly in understanding the role of IL-1 in disease states.

Acetyl zingerone is an IL-17A inhibitor that exhibits potent anti-inflammatory and antioxidant activities. This compound plays a crucial role in protecting melanocytes from DNA damage by inhibiting matrix metalloproteinases and downregulating IL-17A target gene expression. Acetyl zingerone is valuable for research focused on inflammatory skin conditions and mechanisms of cellular protection.

Pentenocin B is an IL-1/β-transferase inhibitor that selectively targets the interleukin-1 signaling pathway. This compound exhibits weak inhibitory activity against IL-1 and β-transferase, which are crucial in mediating inflammatory responses. Pentenocin B is useful for research applications focused on inflammation and related signaling mechanisms.

BC12-4 is a potent inhibitor of interleukin-2 (IL-2) secretion, primarily acting on immune cell signaling pathways. This compound exhibits immunomodulatory activity, making it valuable in the study of cytokine regulation and immune responses. BC12-4 is suitable for research applications focused on autoimmune diseases, transplantation, and cancer immunotherapy.

Pentenocin A is an inhibitor of IL-1β-transferase, also known as interleukin-1 converting enzyme (ICE). This compound displays weak inhibitory activity against the processing of pro-inflammatory cytokine IL-1β, making it useful for studies related to inflammation and immune response. Its applications can extend to research exploring pathways involved in cytokine maturation and signaling, contributing to the understanding of various inflammatory diseases.

Digitoxigenin-3-O-β-D-quinovoside is a potent interleukin-2 (IL-2) inhibitor, exhibiting an IC50 value of 52 nM. This cardiac glycoside is derived from the plant Elaeodendron australe var. integrifolium. It is useful in research applications focused on immune modulation and the investigation of IL-2 signaling pathways, providing valuable insights into related therapeutic areas.

Shegansu B is a potent inhibitor of IL-1β, demonstrating significant inhibition of IL-1β expression in LPS-induced THP-1 cells, achieving an inhibition rate of 64.74%. This compound exhibits noteworthy anti-inflammatory activity, making it a valuable tool for research applications focused on inflammation and immune response modulation. Its selective targeting of IL-1β positions Shegansu B as an important reagent for studies aimed at understanding inflammatory processes and potential therapeutic interventions.

IRBP (651-670) human, mouse is an epitope derived from the conserved region of interphotoreceptor retinoid binding protein (IRBP), functioning primarily as a uveitis-inducing agent. This specific fragment has been shown to elevate levels of pro-inflammatory cytokines, including IL-1β, IL-6, TNFα, IL-17A, and IL-17F, within ocular tissues. Due to its conservation across human, mouse, and bovine species, IRBP (651-670) is valuable in the study of experimental autoimmune uveitis and related inflammatory processes in ocular research.

Xelafaslatide is a Fas receptor antagonist that effectively inhibits Fas receptor signaling, thereby blocking downstream apoptosis and inflammatory pathways. This compound demonstrates significant potential in suppressing neuroinflammation and microglial activation in glaucoma models, offering protection to retinal ganglion cells and preventing axonal degeneration. Xelafaslatide is relevant for research focused on glaucoma and related neurodegenerative conditions.

Dazupegleukin is an interleukin-2 derivative that functions primarily as an immunomodulator. It exhibits antineoplastic properties, making it a valuable candidate for research focused on cancer immunotherapy. The compound can enhance T-cell proliferation and activation, thus playing a significant role in studies aimed at understanding and manipulating immune responses against tumors. Its applications extend to exploring novel therapeutic strategies in oncology.